(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/154417 A1

(51) International Patent Classification:
C07D 413/14 (2006.01) *A61K 31/5377* (2006.01)
A61P 35/00 (2006.01) *A61K 45/06* (2006.01)

(21) International Application Number:
PCT/US2023/012734

(22) International Filing Date:
09 February 2023 (09.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

202210119643.2	09 February 2022 (09.02.2022)	CN
63/308,883	10 February 2022 (10.02.2022)	US
63/328,659	07 April 2022 (07.04.2022)	US
63/437,718	08 January 2023 (08.01.2023)	US

(71) Applicant: **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).

(72) Inventors: **HENDERSON, James, A.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **SCHNADERBECK, Matthew, J.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **HE, Minsheng**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **DAI, Danmei**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **LI, He**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **HU, Bing**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **ZHANG, Yu**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **DING, Man**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **JIANG, Siyi**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **LI, Meiqi**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **SHI, Juanjuan**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).

(74) Agent: **BELLOWS, Brent, R.** et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM,

(54) Title: MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF




FIG. 19

(57) Abstract: An advantageous morphic form of Compound (1) which is also known as CFT7455 and is (S)-3-(6-(4-(morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-l(2H)-yl)piperidine-2, 6-dione and methods to prepare Compound (1) for therapeutic applications are provided. This invention also provides new dosage regimens for administering Compound (1).

[Continued on next page]

WO 2023/154417 A1

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*